Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion. by Jadersten, M, Pellagatti, A, Forsblom, A, Emanuelsson, E, Merup, M, Samuelsson, J, Wainscoat, J, Boultwood, J, Hellstorm-Lindberg, E

Phase II study of subcutaneous alemtuzumab (Campath-1H) therapy of patients with previously untreated chronic lymphocytic leukemia (CLL). by Lundin, J, Kimby, E, Bjorkholm, M, Celsing, F, Hale, G, Hjalmar, V, Merup, M, Petrescu, A, Tullgren, O, Waldmann, H, Mellstedt, H, Osterborg, A

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. by Pellagatti, A, Jädersten, M, Forsblom, A, Cattan, H, Christensson, B, Emanuelsson, E, Merup, M, Nilsson, L, Samuelsson, J, Sander, B, Wainscoat, J, Boultwood, J, Hellström-Lindberg, E

Lenalidomide up-regulates SPARC and inhibits in vitro growth of the malignant clone in myelodysplastic syndrome patients with 5q deletion. by Pellagatti, A, Jadersten, M, Forsblom, A, Cattan, H, Christensson, B, Emanuelsson, E, Merup, M, Nilsson, L, Samuelsson, J, Sander, B, Wainscoat, J, Boultwood, J, Hellstrom-Lindberg, E